437 recruiting. 437 Phase 3, 84 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 437 | Recruiting 437 |
| Phase 2 | 84 | Recruiting 84 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2027-01-04 | 2026-11-05 |
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH | Phase 3 | Recruiting | Amgen | 180 | 2026-12-18 | 2026-11-03 |
| Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy Radical Gastrectomy with D2 Lymphadenectomy, Standard Systemic Therapy for Advanced Gastric Cancer - Gastric Cancer, Peritoneal Metastasis | Phase 3 | Recruiting | Hua Huang, MD, PhD | 170 | 2026-12-01 | 2026-10-16 |
| Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1500 | 2026-10-28 | 2026-11-05 |
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Recruiting | Tanta University | 44 | 2026-10-25 | 2026-11-09 |
| Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer Modular Robot-Assisted Esophagectomy, Conventional Minimally Invasive Esophagectomy - Esophageal Cancer | Phase 3 | Recruiting | Ruijin Hospital | 160 | 2026-10-15 | 2026-10-22 |
| Comparative Study to Evaluate Microbial Versus Porcine Pancreatic Enzyme Therapy in Chronic Pancreatitis Dietary Supplement: Pancreatic enzyme preparation from microbial source that contains amylase (6650 DU), lipase (13000 FIP), and protease (7120 HUT, 15 SAPU, 3000 PC)., Standard of care porcine pancreatic enzyme preparation: amylase (8000 U), lipase (25000 U), and protease (1000 U) - Pancreatitis, Chronic, Exocrine Pancreatic Insufficiency (EPI) | Phase 3 | Recruiting | Asian Institute of Gastroenterology, India | 134 | 2026-10-12 | 2026-10-26 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-11-03 |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks Vonoprazan, Placebo - Symptomatic Non-erosive Gastroesophageal Reflux Disease | Phase 3 | Recruiting | Phathom Pharmaceuticals, Inc. | 500 | 2026-09-25 | 2026-10-07 |
| Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma Cadonilimab, CAPOX regimen, Nivolumab - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Akeso | 900 | 2026-09-24 | 2026-09-29 |
| Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. TETA 4HCl formulation, D-Penicillamine - Wilson's Disease | Phase 3 | Recruiting | Orphalan | 38 | 2026-09-03 | 2026-10-15 |
| A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP) PORT-77, Placebo - Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Phase 2 / Phase 3 | Recruiting | Portal Therapeutics, Inc. | 225 | 2026-09-01 | 2026-09-15 |
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod, Placebo - Ulcerative Colitis (UC) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 150 | 2026-09-01 | 2026-08-18 |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 400 | 2026-08-28 | 2026-11-06 |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-08-25 | 2026-09-21 |
| Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL), Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL), Hepatitis A vaccine (inactivated, adsorbed) - Hepatitis A Vaccine | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 680 | 2026-08-20 | 2026-08-28 |
| Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) Everolimus, Tacrolimus or Cyclosporine - Liver Allograft, Liver Diseases | Phase 3 | Recruiting | Hannover Medical School | 150 | 2026-08-19 | 2026-10-05 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy Saroglitazar Magnesium 1 mg, Placebo - Primary Biliary Cholangitis | Phase 3 | Recruiting | Zydus Therapeutics Inc. | 90 | 2026-08-11 | 2026-09-15 |
Showing 20 of 437. Sign in to see all of them.
Colorectal Neoplasms (62) · Stomach Neoplasms (46) · Pancreatic Neoplasms (37) · Carcinoma, Hepatocellular (35) · Rectal Neoplasms (32) · Crohn Disease (26) · Colonic Neoplasms (24) · Esophageal Neoplasms (22) · Esophageal Squamous Cell Carcinoma (20) · Colitis, Ulcerative (19) · Neoplasms (16) · Biliary Tract Neoplasms (12) · Liver Cirrhosis, Biliary (12) · Neoplasm Metastasis (11) · Liver Cirrhosis (10)
Digestive System Neoplasms (289) · Neoplasms by Site (288) · Gastrointestinal Diseases (280) · Neoplasms (280) · Gastrointestinal Neoplasms (197) · Intestinal Diseases (177) · Colonic Diseases (117) · Intestinal Neoplasms (115) · Rectal Diseases (97) · Liver Diseases (88) · Pathological Conditions, Signs and Symptoms (84) · Neoplasms by Histologic Type (73) · Neoplasms, Glandular and Epithelial (70) · Carcinoma (65)
Oxaliplatin (47) · Fluorouracil (42) · Bevacizumab (35) · Leucovorin (34) · Irinotecan (31) · Capecitabine (27) · Gemcitabine (22) · Folfox protocol (18) · Cisplatin (15) · Drug Therapy (15) · Paclitaxel (14) · 130-nm albumin-bound paclitaxel (12) · Cetuximab (12) · Docetaxel (11) · Radiotherapy (11)
Sun Yat-sen University (19) · Fudan University (15) · Takeda (9) · Janssen Research & Development, LLC (8) · GlaxoSmithKline (7) · Xijing Hospital of Digestive Diseases (7) · Assistance Publique - Hôpitaux de Paris (6) · Eli Lilly and Company (6) · Second Affiliated Hospital of Guangzhou Medical University (6) · Sixth Affiliated Hospital, Sun Yat-sen University (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · Cancer Research UK (5) · Tanta University (5) · Akeso (4) · AstraZeneca (4)
China (209) · United States (129) · France (91) · Italy (86) · Spain (83) · Germany (82) · Canada (77) · United Kingdom (77) · Poland (74) · South Korea (73) · Belgium (71) · Netherlands (67) · Japan (66) · Australia (54) · Taiwan (52)
Matthew Krebs, Dr (4) · Guopei Luo, MD (2) · Lin Shen, MD (2)
PMID 33538338, PMID 10615079, PMID 12372721, PMID 15234753, PMID 17762433, PMID 19936751, PMID 20147682, PMID 21445672, PMID 22226517, PMID 22228948, PMID 24293372, PMID 24616568, PMID 25447852, PMID 25514302, PMID 25752327, PMID 25954089, PMID 28400848, PMID 29061175, PMID 29141563, PMID 29307467, PMID 29471013, PMID 30914290, PMID 30998813, PMID 31070690, PMID 31197699, PMID 31676359, PMID 31784469, PMID 31834056, PMID 31912902, PMID 32293362, PMID 32409830, PMID 32418078, PMID 32471382, PMID 32611448, PMID 32632268, PMID 32702383, PMID 32928136, PMID 32936964, PMID 33148215, PMID 33161160, PMID 33498251, PMID 33553366, PMID 34149034, PMID 34715810, PMID 34726293, PMID 34925649, PMID 35027324, PMID 35221706, PMID 35366831, PMID 35385794
2025 (25), 2023 (24), U10CA180868 (3), 2019 (2), U10CA180820 (2), UG1CA189974 (2), 2017 (1), 5UH3NS115108-04 (1), P30CA033572 (1), R01CA176828 (1), R01CA293394 (1), R01DK098526 (1), R01DK132408 (1), U01CA210170 (1), U10CA180888 (1)